Use of nicotinamide mononucleotide (NMN) for prevention and/or treatment of rheumatoid arthritis and corresponding composition

A single nucleotide, rheumatoid technology, applied in the use of nicotinamide mononucleotide (NMN) for preventing and/or treating rheumatoid arthritis and the field of corresponding compositions, which can solve the problem of large health system problems. cost, etc.

Pending Publication Date: 2022-06-21
NUVAMID SA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a result, patients end up needing to change their daily routines, leave their jobs, and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of nicotinamide mononucleotide (NMN) for prevention and/or treatment of rheumatoid arthritis and corresponding composition
  • Use of nicotinamide mononucleotide (NMN) for prevention and/or treatment of rheumatoid arthritis and corresponding composition
  • Use of nicotinamide mononucleotide (NMN) for prevention and/or treatment of rheumatoid arthritis and corresponding composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0264] K / BxN serum was obtained from a transgenic mouse used as a model of RA. Administration of this serum induced chronic joint inflammation in mice to mimic RA. Dexamethasone, a cortisone derivative, is commonly used as a treatment to combat RA flare-ups. Here, NMN is used in zwitterionic form. KBxN serum and NMN were administered intraperitoneally to mice. Dexamethasone was given subcutaneously.

[0265] Mice were treated for 9 days under the above conditions. Photographs of mouse paws were taken on day 6 of treatment. Blood samples were collected from mice on days 6 and 10 of treatment. Tissue samples were collected on day 10 of treatment (i.e., the day after the end of treatment) for histological analysis. Clinical scores and body weights of mice were measured daily. Determine the clinical score by measuring the thickness of each front and rear paw of the mouse and adding the relevant scores according to Table 1 below:

[0266] [Table 1]

[0267] Hind ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a nicotinamide mononucleotide for use in the prevention and/or treatment of rheumatoid arthritis, a pharmaceutically acceptable derivative thereof or a pharmaceutically acceptable salt thereof, and a composition comprising the same.

Description

field of invention [0001] The present invention relates to the use of nicotinamide mononucleotide (NMN), its pharmaceutically acceptable derivative or its pharmaceutically acceptable salt and the composition containing it in preventing and / or treating rheumatoid arthritis. Background technique [0002] A joint is an assembly, specifically, the assembly of two cartilage-covered bone ends, and the synovial membrane that wraps that assembly. The function of the synovium is to facilitate joint movement by secreting a lubricant (synovial fluid). In particular, inflammatory rheumatic diseases consist of inflammation of the synovium. Excess synovial fluid is then secreted and the synovium thickens abnormally. The soft tissue and bone surfaces of the joint are then damaged. The joint becomes unusually swollen and painful, impeding movement. [0003] Rheumatoid arthritis is a chronic inflammatory rheumatic disease that most commonly affects the hands, wrists (writs) and knees, bu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/706A61K45/06A61P19/02
CPCA61K31/706A61K45/06A61P19/02
Inventor G·伯蒙德L·加龙
Owner NUVAMID SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap